logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals closes special warrants offering that raised nearly C$7M

The Vancouver firm issued 19,605,285 special warrants for $0.35 each and upsized the offering from $5 million

algernon
The money will be used for ongoing research, clinical trials, working capital and general corporate purposes

Algernon Pharmaceuticals Inc (CSE: AGN) (OTCQB:AGNPF) announced Wednesday it closed a private placement offering of special warrants that raised nearly C$7 million. 

The Vancouver-based firm issued 19,605,285 special warrants for $0.35 each and upsized the offering from an initial $5 million target. Gross proceeds totaled $6,861,849.

The money will be used for ongoing research, clinical trials, working capital and general corporate purposes.

READ: Algernon Pharmaceuticals receives first ethics approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Each special warrant consists of one common share and one common share purchase warrant, the latter entitling its holder to another common share at an exercise price of $0.55 for a period of two years.

Algernon, based in Vancouver, is a drug repurposing company that investigates safe, already approved drugs for new disease applications. The company has filed new intellectual property rights around the world for Ifenprodil for the treatment of respiratory diseases and is working to develop a proprietary injectible, slow-release formulation.

In coronavirus (COVID-19) patients, the company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can each release glutamate and cytokines, respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

Algernon has received Health Canada approval to proceed with Phase 2b/3 of a multinational study looking at Ifenprodil, which could be used in the treatment of COVID-19.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham 

 

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.27 CAD

CSE:AGN
Market: CSE
Market Cap: $24.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pure Gold releases more impressive drill results from their underground work...

Pure Gold Mining (CVE: PGM- LSE: PUR) CEO Darin Labrenz joined Steve Darling from Proactive to discuss the company’s most recent drill results that show impressive numbers like 46.7 g/t gold over 7.0 metres and 57.0 g/t gold over 1.0 metre. Labrenz telling Proactive about that underground...

1 hour, 4 minutes ago

2 min read